SCHEMBL25517484

SCHEMBL25517484

COc1ccnc2[nH]cc(-c3cc4ccccc4o3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 6/20 0.52
CDK9 P50750 6/20 0.52
CCNA2 P20248 5/20 0.52
CDK2 P24941 5/20 0.52
CDK5 Q00535 5/20 0.52
CDK5R1 Q15078 5/20 0.52
CCNA1 P78396 4/20 0.52
HTR2A P28223 1/20 0.45
CYP1A1 P04798 2/20 0.44
CYP1B1 Q16678 2/20 0.44
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
ADRA2A P08913 1/20 0.44
DYRK1A Q13627 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25517483 0.84 CCNT1 (0.47) CCNT1CDK9CCNA2CDK2HTR2A
SCHEMBL25156831 0.81 JAK2 (0.52) CCNT1CDK9CCNA2CDK2CDK5
SCHEMBL25157854 0.77 JAK2 (0.54) CCNT1CDK9CCNA2CDK2CDK5
SCHEMBL25158196 0.76 DYRK1A (0.54) CCNT1CDK9CCNA2CDK2JAK2
SCHEMBL25158199 0.75 MAPT (0.45) CCNT1CDK9CCNA2CDK2JAK2
SCHEMBL15436437 0.75 CDK9 (0.53) CCNT1CDK9CCNA2CDK2CDK5
SCHEMBL3985729 0.72 AHR (0.59) CYP1A1CYP1B1KDM4EALDH1A1MAPT
SCHEMBL26174610 0.71 DYRK1A (0.52) CCNT1CDK9CCNA2CDK2CDK5
SCHEMBL414693 0.69 CDK9 (0.54) CCNT1CDK9CCNA2CDK2CDK5
SCHEMBL12347465 0.69 CDK9 (0.73) CCNT1CDK9CCNA2CDK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CCNT1 1162/4885CDK9 94/4885CCNA2 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.